Status:

COMPLETED

A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.

Lead Sponsor:

Tonix Pharmaceuticals, Inc.

Conditions:

Healthy

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

The trial is designed to assess the safety and tolerability of TNX-102 2.4 mg and to compare the bio-availability of TNX-102 2.4 mg and cyclobenzaprine 5 mg tablets under fasting or fed conditions.

Detailed Description

Single-center, randomized, open-label, single-dose, three-way-crossover trial is designed to assess the safety and tolerability of TNX-102 2.4 mg (a dose based on the results of a previous Phase 2a, p...

Eligibility Criteria

Inclusion

  • Healthy adults
  • Male or female
  • Non-smoker
  • 18-55 years old
  • BMI \> 18.5 and \< 30.0
  • With medically acceptable form of contraception (female only).

Exclusion

  • Any clinically significant abnormality or vital sign abnormalities
  • Any abnormal laboratory test
  • History of alcohol or drug abuse or dependence within 1 year and/or positive drug, cotinine, or alcohol tests
  • Use of any drug (within 30 days), supplement, or food (within 14 days) known to induce or inhibit hepatic drug metabolism prior to study medication
  • Positive pregnancy test, breastfeeding or lactating
  • Use of medication other than hormonal contraceptives or topical products, including OTC, natural health products, MAO inhibitors
  • Participation in an investigational study within 30 days prior to dosing
  • Donation of plasma (within 7 days), or donation or loss of blood of 50-499 mL (within 30 days), or of \> 499 mL (within 56 days) prior to dosing.

Key Trial Info

Start Date :

November 18 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 30 2011

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT01490788

Start Date

November 18 2011

End Date

December 30 2011

Last Update

September 11 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

PharmaNet, Inc.

Québec, Quebec, Canada, G1P 0A2

A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults. | DecenTrialz